Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies III: Computed Tomography01:27

Imaging Studies III: Computed Tomography

239
DefinitionComputed Tomography (CT) of the genitourinary (GU) tract is a non-invasive imaging modality that utilizes X-rays and computer processing to generate detailed cross-sectional images of the urinary system, encompassing the kidneys, ureters, bladder, and adjacent structures such as the adrenal glands.PurposeCT scans of the GU tract serve several diagnostic and therapeutic purposes, including:Diagnosis of Urinary Tract Diseases: Detects kidney stones, tumors, cysts, and congenital...
239
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

229
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
229
Imaging Studies I: Kidney, Ureter, and Bladder Studies01:28

Imaging Studies I: Kidney, Ureter, and Bladder Studies

218
Kidney, Ureter, and Bladder (KUB) StudiesKidney, Ureter, and Bladder (KUB) studies are standard diagnostic imaging procedures used to assess the anatomy of the urinary system. They are commonly utilized for patients experiencing abdominal pain or urinary symptoms. By using a simple X-ray of the abdomen, KUB studies can reveal structural and pathological abnormalities within the kidneys, ureters, and bladder. These studies are particularly valuable in diagnosing kidney stones, urinary...
218
Imaging Studies VII: Vascular Imaging01:19

Imaging Studies VII: Vascular Imaging

269
DefinitionRenal angiography, also known as renal arteriography, is an imaging technique used to obtain a comprehensive view of blood flow and the vascular structure of blood vessels in the kidneys and surrounding areas.PurposeRenal angiography detects blood vessel abnormalities in the kidneys, such as aneurysms, stenosis, thrombosis, vascular tumors, and renal artery stenosis. It evaluates kidney function and guides interventional treatments like angioplasty or stent placement.Pre-Procedure...
269
Radiological Investigation I: X-ray and CT01:30

Radiological Investigation I: X-ray and CT

980
Radiological investigations, including X-rays and computed tomography (CT) scans, are critical for diagnosing and evaluating various medical conditions. These imaging techniques provide valuable insights into the body's internal structures, aiding in the detection of abnormalities, assessment of disease progression, and development of treatment strategies. This article delves into two primary radiological investigations, chest X-rays and CT scans, outlining their purpose, procedures, and...
980
Imaging Studies IV: Magnetic Resonance Imaging01:27

Imaging Studies IV: Magnetic Resonance Imaging

204
Introduction:Magnetic Resonance Imaging, or MRI, can include a specialized imaging technique of the urinary system known as Magnetic Resonance Urography (MRU). This radiation-free technique uses strong magnetic fields and radio waves to produce detailed images with the help of a computer. MRU is particularly effective for visualizing fluid-filled structures like the kidneys, ureters, and bladder.Applications of MRI in the Genitourinary SystemKidneys and Ureters: MRI detects tumors, cysts,...
204

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications.

European urology·2026
Same author

<i>APOE</i>-associated disease risk and sex-specific effects in Egyptian Alzheimer's disease: an exploratory study.

Alzheimer's & dementia (New York, N. Y.)·2026
Same author

Outcome-specific risk factors challenge universal dementia prevention priorities: Findings from the Egyptian Dementia Network Registry.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma.

Future oncology (London, England)·2026
Same author

Development and Validation of Quality of Life in Idiopathic Intracranial Hypertension (QOLIH) questionnaire.

Frontiers in neurology·2026
Same author

Upper tract urothelial carcinoma associated with Lynch syndrome.

Current opinion in oncology·2026

Related Experiment Video

Updated: Jan 3, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.1K

Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney Cancer.

Sundeep Agrawal1, Naomi B Haas2, Mohammadhadi Bagheri3

  • 1Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.

JAMA Oncology
|November 22, 2019
PubMed
Summary

Harmonizing eligibility criteria and imaging assessments for adjuvant renal cell carcinoma (RCC) trials improves results. Experts recommend including diverse RCC subtypes and specific tumor stages for better adjuvant therapy evaluation.

More Related Videos

Non-invasive Imaging of Acute Allograft Rejection after Rat Renal Transplantation Using 18F-FDG PET
17:13

Non-invasive Imaging of Acute Allograft Rejection after Rat Renal Transplantation Using 18F-FDG PET

Published on: April 28, 2013

17.4K
In Vivo, Percutaneous, Needle Based, Optical Coherence Tomography of Renal Masses
09:31

In Vivo, Percutaneous, Needle Based, Optical Coherence Tomography of Renal Masses

Published on: March 30, 2015

9.2K

Related Experiment Videos

Last Updated: Jan 3, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.1K
Non-invasive Imaging of Acute Allograft Rejection after Rat Renal Transplantation Using 18F-FDG PET
17:13

Non-invasive Imaging of Acute Allograft Rejection after Rat Renal Transplantation Using 18F-FDG PET

Published on: April 28, 2013

17.4K
In Vivo, Percutaneous, Needle Based, Optical Coherence Tomography of Renal Masses
09:31

In Vivo, Percutaneous, Needle Based, Optical Coherence Tomography of Renal Masses

Published on: March 30, 2015

9.2K

Area of Science:

  • Oncology
  • Nephrology
  • Clinical Trial Design

Background:

  • Adjuvant therapy clinical trials for renal cell carcinoma (RCC) require standardized eligibility criteria and disease assessment methods.
  • Current trial designs may lack uniformity, potentially impacting the interpretability and generalizability of results.

Purpose of the Study:

  • To establish harmonized eligibility criteria for patients.
  • To define standardized radiologic disease assessment definitions for clinical trials investigating adjuvant therapy in RCC.
  • To improve the consistency and interpretability of clinical trial outcomes in the adjuvant RCC setting.

Main Methods:

  • Convened a public workshop with US-based experts in RCC clinical trials, including oncologists, regulators, biostatisticians, radiologists, and patient advocates.
  • Conducted multiple virtual meetings to address identified issues regarding eligibility and radiologic assessment.
  • Synthesized expert consensus on key aspects of trial design for adjuvant RCC therapy.

Main Results:

  • Recommended inclusion of non-clear cell RCC patients, preferably in independent cohorts.
  • Identified specific tumor characteristics (T3-4, N+M0, microscopic R1) that may benefit most from adjuvant therapy.
  • Proposed guidelines for managing patients with renal insufficiency, timing of therapy initiation, and eligibility for different surgical approaches (radical/partial nephrectomy).
  • Advocated for inclusion of patients with microscopically positive margins but no gross disease, and standardized imaging protocols (CT/MRI) based on renal function.
  • Emphasized the importance of biopsy for diagnosis and a uniform approach for evaluating indeterminate radiologic findings and establishing recurrence dates.
  • Highlighted the need to consider patient perspectives on placebo use, unblinding, and research biopsies.

Conclusions:

  • A uniform approach to eligibility criteria and radiologic disease assessment is crucial for enhancing the interpretability of clinical trial results in adjuvant RCC therapy.
  • Standardization will lead to more reliable data and facilitate the development of effective adjuvant treatments for renal cell carcinoma.